Skip to main content
Premium Trial:

Request an Annual Quote

Selventa Raises $5M

NEW YORK (GenomeWeb News) – Life science data analysis firm Selventa has raised $5 million in an equity round, it disclosed in a document filed with the US Securities and Exchange Commission this week.

The company did not say how the funds would be used and did not disclose participants in the financing, though it said nine people invested in the round.

A company official was not available for comment, a spokesperson said.

Based in Cambridge, Mass., Selventa was founded in 2002 and was formerly called Genstruct. On its website it calls itself "a personalized healthcare company that helps pharmaceutical and biotechnology partners find optimal treatments for the right patients through early patient stratification and portfolio optimization."

Its flagship technology, called Genstruct Technology Platform, uses in silico reverse causal reasoning to translate large-scale data "into meaningful, testable molecular mechanisms," it said.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.